EVI1-mediated upregulation of the anti-apoptotic Bcl-xL suggests that BH3-mimetic inhibitor targeting this anti-apoptotic protein could also have therapeutic value, alone or in combinations against EVI1-expressing myeloid malignancies. The gene discussed is RUNX1; the disease is myeloid neoplasm.